Stock Market & Financial Investment News

News Breaks March 21, 2013 15:03 EDT SNY Sanofi says LEMTRADA effect maintained beyond two-year pivotal MS studies Genzyme, a Sanofi Company, announced interim results from the first year of the extension study of LEMTRADA, being developed for the treatment for multiple sclerosis. In this analysis of the first year of the extension study, relapse rates and sustained accumulation of disability remained low among patients who had previously received LEMTRADA in either of the Phase III CARE-MS I and CARE-MS II studies. In these pivotal studies, LEMTRADA was given as two annual courses, at the start of the study and 12 months later. More than 80% of patients did not receive further treatment with LEMTRADA during the first year of the extension study. “These findings are important because they suggest that the benefits of LEMTRADA as observed in the Phase III studies are maintained, even though most patients did not receive further dosing,” said Edward Fox, M.D., Director of the Multiple Sclerosis Clinic of Central Texas, who presented the study results at the annual meeting of the American Academy of Neurology. News For SNY From The Last 14 Days Check below for free stories on SNY the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 21, 2013 07:44 EDT SNY Sachs Associates to host a forum Subscribe for More Information May 20, 2013 17:26 EDT SNY Regeneron, Genentech, Sanofi enter into 'Zaltrap agreement' Subscribe for More Information 11:27 EDT SNY Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva Subscribe for More Information May 17, 2013 08:03 EDT SNY Sanofi reports positive topline results from pivotal Phase III Jakarta study Subscribe for More Information 05:18 EDT SNY Sanofi says JAK2 inhibitor for myelofibrosis met primary endpoint Subscribe for More Information May 15, 2013 15:16 EDT SNY Sanofi systemic sclerosis treatment designated for orphan drug status Subscribe for More Information 05:39 EDT SNY Sanofi, Regeneron announce patient enrollment in two Phase 3 trials Subscribe for More Information May 13, 2013 09:44 EDT SNY Several companies reportedly interested in buying Adcock Ingram, Globes says Subscribe for More Information 07:30 EDT SNY TechConnect to host a summit 2013 National Innovation Summit is being held in Washington, D.C. on May 12-16. May 10, 2013 11:48 EDT SNY Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.